Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Protein-bound paclitaxel Stories

2013-04-01 00:20:20

IGDRASOL will present updates on Cynviloq(TM), its late clinical stage paclitaxel nanoparticle formulation. Highlights include the therapeutic evaluation of Cynviloq(TM) in poorly perfused tumors as well as the potential development of Cynviloq(TM)-based personalized paclitaxel cancer therapy. SAN DIEGO and FOUNTAIN VALLEY, Calif., March 31, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. ("STI"; SRNE) and IGDRASOL announced today that IGDRASOL will be presenting updates of its...

2013-03-07 08:28:01

Transaction establishes a pipeline led by IGDRASOL's late clinical stage paclitaxel-loaded micellar product candidate and enables the combination of IGDRASOL's additional proprietary formulation technology with Sorrento's G-MAB® antibody libraries as a broad platform for next-generation targeted therapeutics. SAN DIEGO and FOUNTAIN VALLEY, Calif., March 7, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. ("STI"; SRNE: OB) today announced that it has signed an exclusive option to...

2013-01-22 20:21:04

MELBOURNE, Australia, Jan. 22, 2013 /PRNewswire/ -- Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE(®) (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two...

2012-11-16 12:26:32

Phase III study results show improvement in overall survival compared to standard treatment SCOTTSDALE, Ariz., Nov. 16, 2012 /PRNewswire-USNewswire/ -- A new cancer drug combination demonstrated significant improvement in overall survival of late-stage pancreatic cancer patients compared to those receiving standard treatment, according to results of a Phase III clinical trial led by physicians from Scottsdale Healthcare's Virginia G. Cancer Center Clinical Trials, a partnership with the...

2012-10-25 07:31:13

MELBOURNE, Australia, Oct. 25, 2012 /PRNewswire/ -- Specialised Therapeutics Australia Pty Ltd today announced that abstracts for the upcoming Society for Melanoma Research meeting have been published online in the organization's official journal at http://onlinelibrary.wiley.com/doi/10.1111/pcmr.12023/abstract. The publication includes an abstract reviewing results from a phase III metastatic melanoma study with ABRAXANE(®) (nanoparticle albumin-bound paclitaxel). In the...

2012-10-12 11:24:12

Micro-miniature particles of chemotherapy will be used as first-line treatment of advanced non-small cell lung cancer WASHINGTON, Oct. 12, 2012 /PRNewswire-USNewswire/ -- LUNGevity Foundation, the nation's largest lung cancer-focused nonprofit, applauds the FDA approval of Abraxane(®) for advanced cases of non-small cell lung cancer providing a much-needed new option for these patients. Non-small cell lung cancer is the most common form of lung cancer, representing 85% of lung...

2011-10-05 14:28:39

Results lead to Scottsdale oncologists heading a large phase III study being conducted worldwide Patients at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare were the first in the nation to participate in a clinical trial to determine the safety, tolerability and effectiveness for usage of a new drug combination consisting of a standard drug called gemcitabine and a drug called nab-paclitaxel for patients with advanced pancreatic cancer.  The results of this...

2011-10-04 07:00:00

Results lead to Scottsdale oncologists heading a large Phase III study being conducted worldwide SCOTTSDALE, Ariz., Oct. 4, 2011 /PRNewswire-USNewswire/ -- Patients at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare were the first in the nation to participate in a clinical trial to determine the safety, tolerability and effectiveness for usage of a new drug combination consisting of a standard drug called gemcitabine and a drug called nab-paclitaxel for patients...

2011-05-10 07:49:00

DALLAS and NEW YORK, May 10, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that it has made significant progress with its CobaCyte(TM) tumor-targeting technology. Using a new proprietary CobaCyte paclitaxel nanoparticle formulation, named Cobraxane(TM), the company's scientists have observed...

2009-12-08 12:46:00

NEW YORK, Dec. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Bulk Paclitaxel - A Global Update of Market Trends & Opportunities http://www.reportlinker.com/p0164226/Bulk-Paclitaxel---A-Global-Update-of-Market-Trends--Opportunities.html World bulk paclitaxel market stands enthused by the effervescent levels of research and development. With market participants injecting resources into developing unique paclitaxel...